	US 12,070,487 B2
	Pharmaceutical composition comprising PIBF protein as active ingredient for prevention or treatment of inflammatory disease
You Sook Cho, Seongnam-si (KR); Jun Pyo Choi, Seoul (KR); In Jeoung Baek, Seoul (KR); Hyouk Soo Kwon, Goyang-si (KR); and So Young Park, Seoul (KR)
Assigned to UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Ulsan (KR); and THE ASAN FOUNDATION, Seoul (KR)
Appl. No. 17/418,684
Filed by UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Ulsan (KR); and THE ASAN FOUNDATION, Seoul (KR)
PCT Filed Dec. 24, 2019, PCT No. PCT/KR2019/018394 § 371(c)(1), (2) Date Jun. 25, 2021, PCT Pub. No. WO2020/138912, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 10-2018-0172897 (KR), filed on Dec. 28, 2018.
Prior Publication US 2022/0088125 A1, Mar. 24, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61P 11/06 (2006.01)

CPC A61K 38/1709 (2013.01) [A61K 45/06 (2013.01); A61P 11/06 (2018.01)]

4 Claims

1. A method of treating an asthma in post-menopausal women, comprising:

administering or dosing a composition comprising a progesterone-induced blocking factor (PIBF) protein as an active ingredient to a subject.